What will happen if I don’t take dabigatran etexilate capsules (Pradaxa) for three days?

Dabigatran etexilate capsule (Pradaxa) is an oral anticoagulant drug commonly used to prevent and treat thrombosis-related diseases, such as non-valvular atrial fibrillation, deep vein thrombosis and pulmonary embolism. For patients with atrial fibrillation, not taking dabigatran etexilate capsules for three consecutive days may cause some potential problems.

1.Increased risk of stroke and thrombosis: The main function of dabigatran etexilate capsule is to inhibit the formation of thrombosis and reduce the risk of stroke and other thrombosis-related risks. Failure to take it for three consecutive days may increase a patient's risk of stroke, especially in patients with atrial fibrillation, who are already at risk for blood clots.

2.Thrombus formation: In patients with atrial fibrillation, atrial fibrillation may cause blood to accumulate in the atria, increasing the risk of thrombosis. Continuous use of dabigatran etexilate helps prevent this, but discontinuing use may make patients more susceptible to blood clots.

3.Unstable anticoagulant status: Dabigatran etexilate capsules have a stable anticoagulant effect, but if not taken for three consecutive days, the patient's anticoagulant status may become unstable, increasing the risk of bleeding and thrombosis.

4.Individual differences: Different patients have individual differences in their responses to drugs. Some patients may not feel obvious changes immediately in a short period of time, but they may have adverse consequences in the long term.

Dabigatran etexilate capsules have been launched in China and have been included in medical insurance. Patients can purchase them domestically. Please consult the local hospital pharmacy for specific prices. The main foreign drug is the original drug of dabigatran etexilate capsules. The cheaper one is the Turkish version of the original drug from Germany. The price of 110mg*60 capsules is about three to four hundred, and the ingredients and efficacy are consistent with the original drug on the domestic market.